RA0129

antibody from Oursmab

Targeting: CD70 CD27L, CD27LG, TNFSF7

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0129

Provider

Oursmab

Product name

Cusatuzumab (Biosimilar Reference Antibody) (CD70)

Antibody type

Monoclonal

Description

Cusatuzumab (also known as ARGX-110) is an investigational humanized monoclonal antibody developed as a targeted therapy for hematologic malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It is designed to eliminate leukemia stem cells and immature malignant blasts that express a specific surface antigen, aiming to address a root cause of disease persistence and relapse. Clinical trials have evaluated its use, often in combination with hypomethylating agents like azacitidine, for the treatment of patients with newly diagnosed or relapsed/refractory AML who are unfit for intensive chemotherapy.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Cusatuzumab (Biosimilar Reference Antibody) (CD70)-RA0129-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.